Upcoming ISPOR Webinar on NICE’s Modernized Data Handling Methods and 5-Year Strategy
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold a virtual event on July 15th at 11:00 AM [...]
Cures 2.0 Key Points Include New $6.5 Billion Federal Research Agency and Expanded RWD in Clinical Trials
Cures 2.0 was introduced on June 22nd. The proposed bipartisan legislation includes components that center on diversifying clinical trials and [...]
How Can Transparency Improve in RWD Studies?
Vice President and Global Head of Epidemiology for Johnson & Johnson Jesse Berlin shared his thoughts on real world evidence (RWE) [...]
Expanded Cures 2.0 Legislation Considers Patient Access and Broadened Use of RWD in Clinical Trials
A recent article, published by the Regulatory Affairs Professionals Society (RAPS), notes that a discussion draft meant to further the [...]
Biogen’s Aduhelm Brings Uncertainty and Concern Regarding Federal Budget
The FDA recently approved Biogen’s Aduhelm for use in patients with Alzheimer’s disease. However, its high price tag—$56,000—means that many [...]
Alzheimer’s Drug Could Equal Federal Government’s Spending on NASA
Biogen’s Aduhelm is exceedingly expensive at $56,000. If covered under Medicare, its cost could approach the federal government’s spending on [...]
HealthVerity’s IPGE Platform Overcomes RWD Challenges
Health Verity’s Identity, Privacy, Governance and Exchange (IPGE) platform takes on many of the challenges associated with real world data [...]
Register Today for Upcoming ISPOR Webinar on Using RWD to Improve Oncology Research and Patient Outcomes in China
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will host a webinar on June 29th, 2021, at 11:00 AM [...]
Biogen’s Aduhelm Unites Drug Pricing Advocates
Healthcare purchasers and employers have formed a coalition, EmployersRx, with the goal of convincing House and Senate members to enact [...]
University of Washington Professor Discusses HEOR and RWD Trends
University of Washington’s Anirban Basu discusses his thoughts on the role of real world data (RWD) in health economics and [...]
Biogen Considers Aduhelm Price Cut as Competing Alzheimer’s Drug Approved by FDA
Biogen and its partner Eisai released a statement regarding Alzheimer’s Drug Aduhelm, which is priced at $56,000 per year. The [...]
HealthVerity Webinar Highlights IPGE Platform in Processing RWD
HealthVerity’s Identity, Privacy, Governance and Exchange (IPGE) platform is streamlining the way real world data (RWD) is used to inform [...]
Is Prescription Drug Price Negotiation a Lasting Trend?
One proposed solution to high prescription drug prices is negotiating directly with manufacturers. Legislative changes allowing Medicare to carry out [...]
New ICER Webinar Series on RWD Case Studies; First Webinar on Alzheimer’s Disease Evidence Report
The Institute for Clinical and Economic Review (ICER) will begin a webinar series highlighting findings from recent draft reports and provide [...]
Researchers Identify Biased Algorithms Prevalent Throughout the US Healthcare Industry
University of Chicago researchers found that biased healthcare algorithms are affecting patient care in hospital settings, as well as interactions [...]
Register Today for Upcoming Webinar on RWD in Oncology Drug Development
A webinar on using real world data (RWD) in the context of oncology drug development will feature insight from cancer [...]
CVS Eliminates 72 Hyperinflated Drugs, Saving $1.2 Billion in 2020
CVS has removed 72 high-priced drugs from its formulary. This move has led to $1.2 billion in savings last year [...]
[Cytel Whitepaper] How Can RWE Drive Oncology Drug Development?
Cytel has published a whitepaper detailing how real world evidence (RWE) can be used in cancer drug development, from preclinical [...]
Upcoming IQVIA Webinars on Preparing for Legislative Changes and New Healthcare Trends
IQVIA is hosting a series of webinars to prepare you and your organization for policy changes, including an on-demand webinar [...]
Friday ISPOR Webinar on Value-Based Pricing
ISPOR will host a webinar on the intersection between price and value. Speakers include Omnicom’s Head of Global Health Accounts [...]
Thursday Webinar on Incorporating SDoH RWD to Improve R&D and Support Outreach Efforts
A webinar on understanding and effectively using social determinants of health (SDoH) data will take place on Friday, June 24th [...]
Clinerion Expands RWD Platform, Offers Unique Healthcare Insights Using EHR Data
Clinerion has expanded its Patient Network Explorer tool to include RWD Radar, a service that provides real world data (RWD) [...]
Five Blue Cross Blue Shield Health Insurance Plans to Incorporate Evio to Cut Costs
Five Blue Cross Blue Shield insurance plans will utilize Evio to reduce healthcare costs, including high prescription drug costs. This [...]
New Report Examines Generic Drug Uptake Trends and Impact on Healthcare Costs
ISPOR’s Value in Health journal recently published an article examining generic drug uptake trends in the United States. Researchers assessed [...]
IQVIA RWD Database Provides Detailed Patient Data
IQVIA’S PharMetrics Plus is a comprehensive database that includes health insurance information and extensive patient data from a variety of [...]